Insider buying
~$45K5,603 sh @ $7.99
Traded Jun 20, 2025 · filed 4 days later
Since the trade +144.0% · S&P 500 +20.5% · to Nov 19
A major shareholder of Nuvectis Pharma paid $45K out of pocket for Nuvectis Pharma shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
NVCT · NASDAQ · Pharmaceutical Preparations
$19.84−0.45 (−2.22%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
Nuvectis Pharma (NVCT) · oqro.io/stocks/NVCT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Insider buying
Traded Jun 20, 2025 · filed 4 days later
Since the trade +144.0% · S&P 500 +20.5% · to Nov 19
A major shareholder of Nuvectis Pharma paid $45K out of pocket for Nuvectis Pharma shares.
Traded Jun 17 – Jun 18, 2025 · largest single transaction ~$226K
Jun 18, 2025~$226K · 28K sh @ $8.05
DetailsOfficial recordTraded May 8 – May 12, 2025 · largest single transaction ~$172K
May 12, 2025~$172K · 21K sh @ $8.11
DetailsOfficial recordInsider buying
Traded Feb 7, 2025 · filed 4 days later
Since the trade +195.7% · S&P 500 +19.2% · to Nov 19
A major shareholder of Nuvectis Pharma paid $1.2M out of pocket for Nuvectis Pharma shares. Shares held went up 9% with this purchase.
Insider buying
Traded Dec 24, 2024 · filed 2 days later
Since the trade +326.7% · S&P 500 +19.1% · to Nov 19
The CEO of Nuvectis Pharma paid $21K out of pocket for Nuvectis Pharma shares. 1 other person at Nuvectis Pharma bought some too, in the same month.
Traded Dec 12 – Dec 13, 2024 · largest single transaction ~$149K
Dec 12, 2024~$149K · 32K sh @ $4.64
DetailsOfficial recordInsider buying
Traded Nov 19, 2024 · filed 1 day later
Since the trade +286.0% · S&P 500 +21.3% · to Nov 19
Nuvectis Pharma's Chief Science & Business Off paid $10K out of pocket for Nuvectis Pharma shares. 2 other people at Nuvectis Pharma bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Nov 15, 2024 · filed 3 days later
Since the trade +300.8% · S&P 500 +22.2% · to Nov 19
The CEO of Nuvectis Pharma paid $98K out of pocket for Nuvectis Pharma shares. 2 other people at Nuvectis Pharma bought some too, in the same month. It was the first purchase in over a year.
Michael J. Carson (Vice President, Finance) sold ~$22K of Nuvectis Pharma
Automatic saleJun 17, 2025~$44K · 5,399 sh @ $8.11
DetailsOfficial recordMay 9, 2025~$88K · 9,850 sh @ $8.95
DetailsOfficial recordMay 9, 2025~$87K · 9,817 sh @ $8.90
DetailsOfficial recordMay 9, 2025~$48K · 5,395 sh @ $8.98
DetailsOfficial recordMay 8, 2025~$22K · 2,400 sh @ $8.97
DetailsOfficial recordMay 8, 2025~$899 · 100 sh @ $8.99
DetailsOfficial recordMay 8, 2025~$871 · 100 sh @ $8.71
DetailsOfficial recordDec 13, 2024~$80K · 17K sh @ $4.70
DetailsOfficial record0 open-market purchases and 0 open-market sales by insiders of NVCT between Jan 12, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 4, 2026. The data provider lists the next release for Feb 9, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 4, 2026 | None | None | None |
| Aug 4, 2026 | None | None | None |
| May 5, 2026 | None | None | None |
| Feb 11, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies